title: [Leukotriene antagonists. A new therapeutic approach in asthma].
abstract: BRONCHIAL INFLAMMATION: Corticosteroids are currently the most important treatment for bronchial inflammation in asthma. SULFIDOPEPTIDE LEUKOTRIENES: These biologically active fatty acids play an important role in the inflammation process in asthma. A NEW THERAPEUTIC APPROACH: Some leukotriene receptor antagonists and synthesis inhibitors are effective and safe treatment for mild to moderate asthma. GLOBAL STRATEGY: The role of these new drugs in the management of asthma remains to be defined on the basis of comparative clinical trials with the standard reliever treatment: inhaled corticosteroids.
authors.affiliation: Clinique des Maladies respiratoires, Hôpital Arnaud de Villeneuve, Montpellier. PChanez.asmanet@Parisnet
authors.forename: P
authors.initials: P
authors.lastname: Chanez
authors.forename: Y H
authors.initials: YH
authors.lastname: Bougeard
authors.forename: I
authors.initials: I
authors.lastname: Vachier
authors.forename: P
authors.initials: P
authors.lastname: Godard
mesh_terms: D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology
chemical_list: D020024:Leukotriene Antagonists; D015289:Leukotrienes